Business

Endonovo Therapeutics Releases Comparative Analysis Demonstrating

Endonovo Therapeutics Releases Comparative Analysis Demonstrating.

articleEndonovo Therapeutics, Inc.July 28, 20225/company/endonovo-therapeutics-inc/news/endonovo-therapeutics-releases-comparative-analysis-demonstrating
Endonovo Therapeutics Releases Comparative Analysis Demonstrating

About this update from Endonovo Therapeutics, Inc.

[{"type":"text","content":"\n More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical characteristics comparisons for both devices were included in FDA-clearance material for both company’s Pulsed Electric Magnetic Frequency (PEMF) products, which are designed to alleviate post-operative reduction of pain and edema (swelling). Comparison of SofPulse® to RecoveryRx® in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse® medical device. The RecoveryRx® device requires 7 days to 14 days to provide medical treatment efficacy for post-operative pain and edema reduction compared with less than 18 hours of treatment needed for Endonovo’s SofPulse® to achieve medical efficacy. In converting comparison results to clinical treatment time, RecoveryRx® requires at least 84 hours to 336 hours of continuous treatment to achieve medical efficacy, while medical efficacy for Endonovo’s SofPulse® is achieved in 18 hours of treatment.” Although both SofPulse® and RecoveryRx® are PEMF devices, there is little comparison in market, efficacy or effectiveness between the two. Collier pointed out: “Recover Rx® is a low-cost, less effective PEMF treatment option to SofPulse®. Both products provide an alternative to potentially addictive opioids for post-surgical pain management. However, side-by-side comparisons show that SofPulse® PEMF design and technical characteristics deliver more effective treatments. SofPulse® is also able to deliver medical efficacy much quicker and more efficiently then the less powered limited RecoveryRx® device.”Technical analysis detailed in the comparison studies indicated: MINIMUM REQUIRED TREATMENT TIME FOR MEDICAL EFFICACY – SofPulse® delivers medical efficacy of treatment in two 15-minute trea...

More updates from Endonovo Therapeutics, Inc.